NEW YORK – In an interim analysis of the Phase III IMpower110 study, advanced non-small cell lung cancer patients receiving first-line treatment with atezolizumab (Tecentriq) and high PD-L1 expression lived longer compared to those on chemotherapy, according to Roche subsidiary Genentech.

The drugmaker will present data from this trial at an upcoming meeting and submit this data to the US Food and Drug Administration and the European Medicines Agency.